Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02637531
Title A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

melanoma

carcinoma

lung non-small cell carcinoma

Therapies

Pembrolizumab

IPI-549

Age Groups: adult
Covered Countries USA


No variant requirements are available.